Portal de Periódicos da CAPES

Effects of hydroxyurea on F‐cells in sickle cell disease and potential impact of a second fetal globin inducer

2016; Wiley; Volume: 92; Issue: 1 Linguagem: Inglês

10.1002/ajh.24590

1096-8652

Yan Dai, José Sangerman, Mehdi Nouraie, Aidan Faller, Patricia O’Neal, Angela Rock, Oluwakemi Owoyemi, Xiaomei Niu, Sergeï Nekhai, Dashmeet Maharaj, Shauiying Cui, Robert E. Taylor, Martin H. Steinberg, Susan P. Perrine,

Erythrocyte Function and Pathophysiology

To the Editor: Biochemical, epidemiologic, clinical, and genetic research over several decades has shown that any increment in fetal hemoglobin (HbF) reduces the clinical severity of sickle cell anemia, with significantly improved survival in US patients with HbF levels above the 75% percentile (8.6%) or with an absolute HbF ≥ 0.5 g/dL with hydroxyurea (HU) treatment 1, 2. While having 100% F-cells results in a benign condition in compound heterozygotes for HbS and hereditary persistence of HbF (HPFH), a level of 70–75% F-cells has been observed in the milder haplotypes, such as the Arabian-Indian haplotype 3-5. Perhaps the most important protector of the sickle erythrocyte from deoxy HbS polymer-induced injury is the concentration of HbF/F-cell. A recent analysis of a population of African patients found low concentrations of HbF/F-cells in sickle cell patients in Tanzania, supporting the importance of this parameter 6. The amount of HbF/F-cell required to entirely prevent HbS polymerization was recently proposed as a therapeutic target 1. To investigate the impact of HU on HbF expression parameters other than total HbF in adult patients, we analyzed F-cells and HbF/F-cell in 56 adult sickle cell disease patients attending a sickle cell clinic for routine care, of whom 33 (60%) were taking HU at modest stable doses of 1,000–1,500 mg/day. Subjects were 20–65 years of age, with median age 31 years; 45% were females. Patients with an acute illness or transfusion within 4 weeks were not included. Proportions of F-cells and mean fluorescent intensity (MFI) of F-cells were analyzed from heparinized peripheral blood by flow cytometry. Cells were stained with a specific HbF antibody (Becton–Dickinson). F-cells and mean fluorescence intensity of positive cells was determined using Cell Quest software and used as an estimate of HbF/F-cell. HbF was analyzed by HPLC (Variant). The mean HbF in HU-treated subjects was 8.8% compared to 5.0% in untreated subjects (Fig. 1A), a level nearly identical to that observed in the Multi-Center Study of Hydroxyurea that led to its FDA approval. Mean % F-cells was 34% in HU-treated subjects compared to 22.9% in untreated subjects (P = 0.01, t-test), shown in Fig. 1B. Fourteen of the 33 (42%) of HU-treated subjects demonstrated F-cell proportions ≥ 40%. Mean fluorescent intensity of F-cells in untreated patients compared to HU-treated patients was 37 vs. 48 fluorescence units, respectively, shown in Fig. 1B (P = 0.01). Several recently identified targeted HbF therapeutic inducing agents which act through differing mechanisms to increase fetal globin mRNA, HbF, and F-cells in vitro and in vivo, including sodium 2,2 dimethylbutyrate (ST20), benserazide (BEN), and the LSD-1 inhibitor RN-1 were evaluated for effects on HbF expression in erythroid progenitor cells cultured from at least 10 sickle cell patients 3. All therapeutic candidates significantly induced fetal globin mRNA levels by 2.5- to 10-fold above untreated control cells from the same patients (Fig. 1C); mean increases above control were 2.5- to 2.8-fold with HU, RN-1, or ST20 (all, P < 0.01); 5.8-fold with BEN (P < 0.001); and 7-fold with combined treatment with BEN and HU (P = 0.01), analyzed by a nonparametric test. A,B: Mean levels of HbF, F-cells, or MFI in sickle cell patients who were taking HU (dark bars) were significantly higher in treated than in untreated patients. C: Fetal (γ)-globin mRNA in erythroid progenitors cultured from sickle cell patients is significantly increased (*) with added therapeutics compared to untreated controls from the same patient, from 2.5- to 2.8-fold with ST20, RN-1, or HU, 5.8-fold with BEN (P < 0.001), and 7-fold with BEN + HU (n = 10, P = 0.011). Standard deviation is shown by the vertical bars. D: Diagram of the Pathway analysis, demonstrating that the main effect of hydroxyurea (HU) is due to increases in % F-cells, which in turn contribute to total HbF. Therapeutic targets for amelioration of clinical severity of sickle cell disease have been proposed as 20–30% HbF, 70–75% F-cells, and 10 pg HbF/cell, twice the threshold of 4–6 pg/cell which is the minimum previously detectable in flow cytometry assays 1. F-cells undergo selective survival and have longer lifespans than non-F cells 3-5. We used a pathway analysis to deconstruct the total effects of HU as either direct (HbF) or indirect (mediated by F-cell percentage). Pathway analysis tests a hypothetical pathway from predictors to responses against observed data using multiple regression equations. Standardized regression coefficients are computed for each relationship, adjusted for the other relationships, and shown next to each line connecting predictors to responses, and is shown for the patient data in Fig. 1D. This analysis indicates that HU contributes first to higher proportions of F-cells (r = 0.47, P < 0.001), and secondly to the amount of HbF (r = 0.85, P < 0.01), whereas, in contrast, a direct effect of HU to HbF was not statistically significant (r = 0.09, P = 0.3). In this analysis, 82% of the total effect of HU on HbF is an indirect effect mediated by F-cells. These data suggest that addition of a second, or perhaps multiple, HbF inducers may produce higher concentrations of HbF content in erythroid cells which differentiate with, or are primed by, HU. The findings here particularly suggest that addition of benserazide as a second therapeutic with HU may induce HbF expression closer to therapeutic targets proposed. As individual patients have highly variable baseline HbF expression patterns, monitoring these parameters may guide treatments to ameliorate clinical severity and indicate when multiple therapies are warranted. Y. Dai, J. Sangerman, A. D. Faller, D. Maharaj and X. Niu performed assays; A. Rock, O. Owoyemi, and P. Oneal obtained clinical correlations; S. Perrine, M. Nouraie, M. Steinberg, analyzed results and wrote the paper. M. Nouraie performed statistical analyses. S. Nekhai, S. Cui, and R. Taylor reviewed the manuscript. Yan Dai,1,2 Jose Sangerman,3 Mehdi Nouraie,4 Aidan D. Faller,3 Patricia Oneal,5 Angela Rock,5 Oluwakemi Owoyemi,5 Xiaomei Niu,5 Sergei Nekhai,5 Dashmeet Maharaj,3 Shauiying Cui,6 Robert Taylor,5 Martin Steinberg,6,7 And Susan Perrine1,2,3,5,8 1Cancer Center, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts; 2Cancer Center, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts; 3Hemoglobinopathy Thalassemia Research Unit, Boston University School of Medicine, Boston, Massachusetts; 4Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; 5Center for Hemoglobin Research in Minorities (CHaRM), Howard University, Washington, District of Columbia; 6Hematology Oncology, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts; 7Medicine, Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts; 8Phoenicia Biosciences, Weston, Massachusetts